WMIC: ART debuts Optix MX3

Optical molecular imaging device developer Advanced Research Technologies (ART) has introduced its Optix MX3 flourescent imaging system at the 2009 World Molecular Imaging Congress (WMIC) in Montreal this week.

The compact Optix MX3 system offers a completely re-engineered and redesigned Optix platform that incorporate new technology, such as the capability to image red fluorescent proteins, Q-dots, and the complete spectrum ranging from 450 nm to 850 nm with the support of a tunable laser, according to the Montreal-based ART.

The system utilize's the company's proprietary time-domain technology, which allows measurement of the light's time of arrival and it can detect target signals within the organs of small animals.

The Optix MX3 also has the capability to recover fluorescence lifetime, which can be used to separate and quantify fluorescent probe distributions depending on their respective biochemical environment. In addition, the Optix MX3 features a CT fusion software package that allows researchers to export a scan in DICOM format, and fuse it with micro-CT for a full 3D anatomic reference.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.